Keywords: R&D spending, European Union, USA,Japan, Pharmaceuticals, Biotechnology
Corporate R&D investment in 2008: a global increase with EU companies leading USA and Japan; Pharma/biotech top sectors
Article | 16 November 2009
Worldwide corporate R&D investment increased by 6.9% in 2008, in spite of the economic crisis, according to the 2009 "European Union Industrial R&D Investment Scoreboard" released today on the European Commission’s web site.
With an 8.1% increase, the R&D investment growth of EU companies, defined as those having headquarters within the EU, is significantly higher than US ones for the second year, at 5.7%, and Japanese firms, at 4.4%. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
